Outcomes | Peak Bilirubin (Cutpoint 160 mmol/L [9.4 mg/dL]) | Peak Bilirubin (Cutpoint 200 mmol/L[11.7 mg/dL]) | ||||||
---|---|---|---|---|---|---|---|---|

≥160 (61) | <160 (67) | OR (CI)^{†} | P | ≥200 (20) | <200 (108) | OR (CI)^{†} | P | |

Blindness attributable to ROP ( n = 15) (%) | 4 (7%) | 11 (16%) | 0.357 (0.107–1.189) | .083 | 1 (5%) | 14 (13%) | 0.353 (0.044–2.851) | .630 |

Neurodevelopmental impairment ( n = 21) (%) | 9 (15%) | 12 (18%) | 0.793 (0.309–2.038) | .390 | 6 (30%) | 15 (14%) | 2.657 (0.884–7.990) | .074 |

↵† The ORs for Blindness represent a comparison of the proportion of subjects with peak bilirubin less than 160 and 200, with the proportion of subjects with peak bilirubin greater than or equal to 160 and 200, respectively. The ORs for Neurodevelopmental Impairment represent a comparison of the proportion of subjects with peak bilirubin greater than or equal to 160 and 200, with the proportion of subjects with peak bilirubin less than 160 and 200, respectively.